STOCK TITAN

Relief Therapeutics Holding SA - RLFTY STOCK NEWS

Welcome to our dedicated news page for Relief Therapeutics Holding SA (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on Relief Therapeutics Holding SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Relief Therapeutics Holding SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Relief Therapeutics Holding SA's position in the market.

Rhea-AI Summary
Relief Therapeutics announces an extraordinary general meeting to overhaul the Board of Directors, including key agenda items and proposed new members.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary
Relief Therapeutics Holding SA grants exclusive license to Eton Pharmaceuticals, Inc. for commercialization of GOLIKE products in the U.S., marking a strategic move in partnership models. The agreement includes upfront payment, sales milestones, and royalties. PKU GOLIKE's net sales exceeded $1 million in the U.S. in Q4 2023, with additional medical food line extensions for rare metabolic diseases planned for launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.08%
Tags
none
-
Rhea-AI Summary
Relief Therapeutics Holding SA renews a CHF 50 million Share Subscription Facility agreement with GEM Global Yield LLC, showcasing commitment to strategic transformation. The Company aims to enhance financial flexibility and development initiatives over the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
Rhea-AI Summary
Relief Therapeutics Holding SA (RLF) announced its intent to transition from direct marketing and sales to a partnership-based model to focus on R&D activities. The company aims to streamline its commercial operations and reinforce its foundational strengths, particularly affecting its GOLIKE® franchise. Relief remains committed to supporting patients benefiting from PKU GOLIKE® and is exploring potential partnerships for the continued commercialization and expansion of its franchise and the expected commercial launch of RLF-OD032 in early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
partnership
-
Rhea-AI Summary
Relief Therapeutics Holding SA (RLF) announces the stepping down of CEO Jack Weinstein and the appointment of Michelle Lock as the interim CEO. Michelle Lock, a highly experienced pharmaceutical executive, will be taking over the role immediately. She has nearly 30 years of biopharmaceutical strategic, operational, and commercialization experience and has previously held executive roles at Covis Pharma Group and Acceleron Pharma Inc. Relief is excited to have Michelle lead the company and is looking forward to a new chapter under her leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
-
Rhea-AI Summary
Relief Therapeutics announces over 400,000 outstanding ADRs, a key requirement for NASDAQ listing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
Rhea-AI Summary
RELIEF THERAPEUTICS to present at H.C. Wainwright Global Investment Conference on Sept. 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.68%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Relief Therapeutics announces that its state-of-the-art laboratory in Balerna, Switzerland has been audited and approved by Swissmedic, the national authorization and supervisory authority for drugs and medical products. The laboratory meets Good Manufacturing Practice (GMP) standards and offers a comprehensive suite of analytical and development services. The lab is designed to meet forthcoming pharmaceutical challenges and is fully integrated with current R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Relief Therapeutics Holding SA

OTC:RLFTY

RLFTY Rankings

RLFTY Stock Data

17.11M
8.39M
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Geneve